» Articles » PMID: 2360815

Preliminary Study of the Pharmacokinetics of Oral Amifloxacin in Elderly Subjects

Overview
Specialty Pharmacology
Date 1990 May 1
PMID 2360815
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Amifloxacin pharmacokinetics after a single oral dose in healthy elderly subjects were determined. Five males and five females aged 65 to 79 years and having creatinine clearances of 39.3 to 87.2 ml/h per kg of body weight were given a 200-mg amifloxacin caplet following an overnight fast. Mean (standard deviation) pharmacokinetic parameters for amifloxacin were as follows: maximum observed concentration in plasma, 1.13 (0.48) and 1.95 (0.52) micrograms/ml; half-life, 5.37 (0.96) and 4.47 (0.87) h; total plasma clearance (unadjusted for fraction absorbed), 259 (53) and 199 (55) ml/h per kg; renal clearance, 113 (20) and 86 (26) ml/h per kg; Varea/F (Varea is volume of distribution; F is fraction absorbed), 2.05 (0.75) and 1.28 (0.39) liter/kg; and amifloxacin excreted in the urine, 42.5% (14.5%) and 42.8% (10.6%) for males and females, respectively. There were no statistically significant differences in pharmacokinetic parameters between sexes that could not be attributed to differences in body weight. Except for a modest 23% reduction in renal clearance and the suggestion of reduced bioavailability, mean values of pharmacokinetic parameters for elderly male subjects were similar to those previously determined for younger male volunteers. Therefore, a modification in amifloxacin dosage regimen based solely on age may not be necessary.

Citing Articles

Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.

Cheng D, Xu W, Liu C World J Gastroenterol. 2007; 13(17):2496-503.

PMID: 17552035 PMC: 4146770. DOI: 10.3748/wjg.v13.i17.2496.

References
1.
Wentland M, Bailey D, Cornett J, Dobson R, Powles R, WAGNER R . Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships. J Med Chem. 1984; 27(9):1103-8. DOI: 10.1021/jm00375a003. View

2.
Gonzalez M, Uribe F, Moisen S, Fuster A, Selen A, Welling P . Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother. 1984; 26(5):741-4. PMC: 180005. DOI: 10.1128/AAC.26.5.741. View

3.
Brumfitt W, Franklin I, Grady D, Hamilton-Miller J, Iliffe A . Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother. 1984; 26(5):757-61. PMC: 180008. DOI: 10.1128/AAC.26.5.757. View

4.
Neu H, Labthavikul P . Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent. Diagn Microbiol Infect Dis. 1985; 3(6):469-78. DOI: 10.1016/s0732-8893(85)80003-1. View

5.
Neuman M . Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988; 14(2):96-121. DOI: 10.2165/00003088-198814020-00003. View